

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-01-14** | Period of Report: **2013-01-09**
SEC Accession No. [0001181431-13-003110](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

Stereotaxis, Inc.

CIK: [1289340](#) | IRS No.: [943120386](#) | State of Incorporation: **DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: [000-50884](#) | Film No.: [13528028](#)
SIC: **3845** Electromedical & electrotherapeutic apparatus

Mailing Address
4320 FOREST PARK
AVENUE
SUITE 100
ST. LOUIS MO 63108

Business Address
4320 FOREST PARK
AVENUE
SUITE 100
ST. LOUIS MO 63108
314-678-6100

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 01/09/2013

Stereotaxis, Inc.

(Exact name of registrant as specified in its charter)

Commission File Number: 000-50884

Delaware
(State or other jurisdiction of
incorporation)

94-3120386
(IRS Employer
Identification No.)

4320 Forest Park Avenue, Suite 100, St. Louis, MO 63108
(Address of principal executive offices, including zip code)

314-678-6100
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On January 9, 2013, Stereotaxis, Inc. (the "Company") received notification from the NASDAQ Stock Market ("NASDAQ") that the Company had regained compliance with the minimum market value of publicly held shares requirement ("MVPHS Requirement") of \$15,000,000 for a minimum of 10 consecutive business days as set forth in NASDAQ Listing Rule 5450(b)(3)(C) (the "Rule").

Previously, on June 25, 2012, the Company received a written deficiency notice from NASDAQ advising the Company that it did not maintain a minimum MVPHS of \$15,000,000 for the 30 consecutive business days prior to the date of the letter. Since, as described in the foregoing paragraph, the Company has regained compliance with the Rule, NASDAQ advised that it considers this matter to be closed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Stereotaxis, Inc.

Date: January 14, 2013

By: /s/ Karen Witte Duros

Karen Witte Duros

Sr. Vice President, General Counsel